approved EB-1B
Director Of Business And Research Strategy
Biochemistry · India · 2023-04-07
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.
Framework Evaluation
3 of 2 criteria metScholarly Publications (Met)
The petitioner authored 16 peer-reviewed articles and 2 book chapters in international journals.
Original Research Contributions (Met)
The petitioner's work on Mavacamten and muscle physiology is widely cited and recognized as groundbreaking by experts.
Peer Review Judging (Met)
The petitioner completed at least 25 reviews of the work of others in the field.
Why This Petition Was Approved
The petition was approved based on 16 peer-reviewed articles, 1 preprint, and 2 book chapters which garnered 1,035 citations. The petitioner also demonstrated international recognition through 25 peer reviews and significant contributions to the mechanism of action for the drug Mavacamten. These metrics satisfied the EB-1B criteria for scholarly publications and original research contributions.
Evidence
Evidence Types
Peer Reviewed Publications
Citations
Reference Letters Independent
Judging Experience
Original Contributions
Evidence Submitted
- 16 peer-reviewed articles
- 1 preprint article
- 2 book chapters
- 1,035 citations (Google Scholar)
- 25 peer reviews conducted
- Ph.D. in Physiology
- Offer of ongoing employment from sponsoring employer
Similar Cases
Postdoctoral Researcher
Biotechnology · China
WeGreened EB-1B rfe approved
Massachusetts 557 days 2025-10-20
The petition was approved based on the petitioner's 14 peer-reviewed journal articles and 655 citations, which established his international influence in cell biology. His completion of 25 peer reviews for leading journals satisfied the judging criteria for EB-1B. The evidence successfully demonstrated his original scientific research contributions to the field of cancer treatment and molecular biochemistry.
Assistant Professor
Research and Development · India
WeGreened EB-1B approved
7 days 2023-09-25
The petition was approved based on meeting the EB-1B criteria for international recognition as an outstanding researcher. Key metrics included 14 peer-reviewed scientific articles, one book chapter, and 201 citations demonstrating significant influence. Additionally, the petitioner's record of 100 peer reviews for acclaimed journals established his prestige and standing in the field.
Research Assistant
Pharmaceuticals · China
WeGreened EB-1B approved
Minnesota 761 days 2025-04-01
The petition was approved based on the petitioner's 15 peer-reviewed articles and 215 citations, with several papers ranking in the top 10% of the field. Additionally, her participation in 10 peer reviews for prestigious journals and the global application of her research by independent scholars satisfied the EB-1B requirements.
Scientist
Biotechnology · India
WeGreened EB-1B approved
Washington 14 days 2025-08-12
The petition was approved based on 12 peer-reviewed journal articles and 647 citations demonstrating significant influence. The petitioner also provided evidence of 10 manuscript reviews and research funding from prestigious institutions like the NIH. These metrics satisfied the EB-1B criteria for scholarly publications, original contributions, and peer review.
Frequently Asked Questions
A approved EB-1B (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.
Browse More Cases
Case data sourced from publicly available petition decisions and case studies. Decision date: 2023-04-07.
Browse all casesAt a Glance
Outcome approved
Processing 8 days
Criteria Met 3 / 2
Evidence Types 5
EB-1B Case Data
Scraped Case Data
Total Cases 63
Success Rate 98.4%
Sustained 62
Dismissed 1
Related Pages
Get Case Insights
Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.
Join Waitlist